1228551-75-4 Usage
Molecular Weight
272.11 g/mol This is the mass of one mole of the compound, based on the atomic weights of the elements that make it up.
Structure
1H-Pyrrolo[2,3-b]pyridine-3-carboxylic acid, 5-bromo-2-methyl-, methyl ester This is a description of the compound's structure, indicating the arrangement of atoms and the type of bonding.
Family
Pyridine carboxylic acid This indicates that the compound belongs to a specific group of related chemical compounds.
Derivative
Methyl ester of 5-bromo-2-methyl-1H-pyrrolo[2,3-b]pyridine-3-carboxylic acid This indicates that the compound is derived from another compound through a chemical modification.
Use
Organic synthesis and pharmaceutical research This indicates that the compound is used in the creation of new compounds and in the development of pharmaceuticals.
Applications
Development of drugs This indicates that the compound has potential applications in the creation of new drugs.
Biological Activities
Exhibits diverse biological activities and pharmacological properties This indicates that the compound has a range of effects on biological systems.
Importance
Important intermediate in medicinal chemistry This indicates that the compound is a valuable building block in the synthesis of other pharmaceutical compounds.
Check Digit Verification of cas no
The CAS Registry Mumber 1228551-75-4 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,2,2,8,5,5 and 1 respectively; the second part has 2 digits, 7 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 1228551-75:
(9*1)+(8*2)+(7*2)+(6*8)+(5*5)+(4*5)+(3*1)+(2*7)+(1*5)=154
154 % 10 = 4
So 1228551-75-4 is a valid CAS Registry Number.
1228551-75-4Relevant articles and documents
1, 7 - DIAZACARBAZOLES AND THEIR USE IN THE TREATMENT OF CANCER
-
, (2011/07/07)
The invention relates to 1, 7-diazacarbazole compounds of Formula (I), (I-a) and (I-b) which are useful as kinase inhibitors, more specifically useful as checkpoint kinase 1 (chk 1) inhibitors, thus useful as cancer therapeutics. The invention also relates to compositions, more specifically pharmaceutical compositions comprising these compounds and methods of using the same to treat various forms of cancer and hyperproliferative disorders, as well as methods of using the compounds for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, or associated pathological conditions.